X. Mariette

WCN26-6846 CIRCULATING KIDNEY INJURY MARKERS AND INTERLEUKIN-10 IDENTIFY NON-CRITICALLY ILL COVID-19 PATIENTS AT RISK OF DEATH

Olivia Lenoir, Florence Morin, Léa Resmini, Mohamad Zaidan et autres

fr, de (code pays fourni par la source)

OP0145 TRANSCRIPTOMIC STRATIFICATION PREDICTS RESPONSE TO RITUXIMAB, ABATACEPT OR THE ASSOCIATION OF HYDROXYCHLOROQUINE AND LEFLUNOMIDE IN 3 RANDOMIZED CONTROLLED CLINICAL TRIALS IN SJÖGREN'S DISEASE

Bruno Chevet, Valérie Devauchelle‐Pensec, Elena Pontarini, Valentin Baloche et autres

Background: Sjögren's disease (SjD) is a clinically and biologically heterogeneous disease. To date, no phase-III trial showed efficacy in reducing the symptoms or systemic activity of the disease and no immunomodulatory drug has been marketed. We have previously demonstrated using whole blood …

fr, gb, nl, us, be, es (code pays fourni par la source)

Optimisation de la réponse vaccinale contre le pneumocoque à l’initiation du méthotrexate dans la polyarthrite rhumatoïde (VACIMRA) : un essai randomisé ouvert

Jacques Morel, E. Dernis, C. Roux, C. Richez et autres

fr, mc (code pays fourni par la source)

POS0512 ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING

R. Alten, C. Rauch, M. Chartier, Michael T. Nurmohamed et autres

de, fr, nl, us, gb, es, it, au, ch (code pays fourni par la source)

POS0107 ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

R. Alten, C. Rauch, M. Chartier, Michael T. Nurmohamed et autres

de, fr, nl, us, gb, es, it, au, ch (code pays fourni par la source)

Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients

Adeline Ruyssen‐Witrand, Stéphanie Rouanet, B. Combe, Maxime Dougados et autres

OBJECTIVE: To determine whether a functional single-nucleotide polymorphism in the B-cell activating factor (BAFF) gene correlates with the response to treatment with rituximab (RTX) in RA. METHODS: SMART is a randomized open trial (NCT01126541) assessing two strategies of re-treatment in patients responding …

fr (code pays fourni par la source)

IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy

Antoine Jacquet, Arnaud François, C. Frangié, Yasmina Yahiaoui et autres

The association between seronegative spondyloarthro- pathies and IgA nephropathy is well documented, mainly in cases of ankylosing spondylitis (AS). However, although these diseases have been associated, the physiopathological links between each other appear unclear. Anti-TNFalpha agents have transformed the outcome of axial …

fr (code pays fourni par la source)